We are in a better position this year than the last year and there has been a conscious decision from our side to enter into newer segment such as branded generics and newer markets where there is some credit oriented business, said Vivek Siddharth, COO, Caplin Point Laboratories.

“The good news is that several of our long-term investors had called us and they have had good things to say,” he added.

We have managed to increase our cash and cash surpluses from 100 plus crore to 125 crore, he said.

On stock front, Siddharth said, “Since 1994 till 2018 there has not been a single stock that has been sold from the promoter stake. We will be putting out press release soon on that.”

"We are looking at growing about 20-25% year-on-year," he added.